Clinical Trial Update: Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis [Phase 2]

View source ↗

Summary

This entry reports a Phase 2 clinical trial evaluating the efficacy and safety of CM336 Injection for primary light-chain amyloidosis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis

Drugs mentioned

• CM336 Injection (CM336)

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Primary Light-Chain Amyloidosis | Phase 2 | Status: RECRUITING